Tempus AI Buys Personalis in $1.5B Deal to Advance Blood-Based Cancer Detection
The deal combines advanced cancer diagnostics with Tempus’ AI platform for improved surveillance.
/ 13 items
#TEM↓
Tempus AI Shares Rise on New Angiosarcoma Research Collaboration
Tempus AI announces research collaboration with Angiosarcoma Awareness, analyzing ~600 patient records with paired DNA/RNA data to accelerate rare cancer insights.
Tempus AI Gets FDA Green Light for Simpler Tumor-Only Cancer Test
Tempus AI gets FDA approval for tumor-only cancer DNA test, making diagnosis easier and boosting future revenue potential.
Tempus AI Q1 2026: Revenue Beats Expectations, But Stock Drops on Wider Losses
Tempus AI revenue rose 36% to $348M, but losses widened. Stock fell ~7% after weaker profit and cautious outlook.
TD Securities Sees Strong 2026 Growth for Tempus AI
TD Cowen upgraded Tempus AI to Buy, $65 target, citing strong growth in AI pharma tools despite recent stock drop.
Tempus AI Gets a $100 Price Target – Why Mizuho Sees Big Upside in Precision Oncology
Mizuho starts coverage on Tempus AI with Outperform rating and $100 price target. Leader in AI-powered precision oncology in a $40B market growing 30% annually—growth undervalued today.